Pharmaceutical Properties of a Tinted Formulation of a Biguanide Antiseptic Agent, Olanexidine Gluconate
Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properti...
Saved in:
Published in | Biological & pharmaceutical bulletin Vol. 45; no. 2; pp. 220 - 225 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Japan
The Pharmaceutical Society of Japan
01.02.2022
Japan Science and Technology Agency |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properties compared with OLG-C and povidone iodine (PVP-I). We evaluated the influence of the additives on the antimicrobial activity and adhesiveness of medical adhesives to OLG-T-applied skin by in vitro time-kill/ex vivo micropig skin assays and a peel test using excised micropig skin, respectively. In the in vitro time-kill assay, the bactericidal/fungicidal activity of OLG-T and OLG-C were equivalent. In the ex vivo micropig skin assay, their fast-acting and persistent bactericidal activities against vancomycin-resistant Enterococcus faecalis were higher than that of PVP-I. In the peel test, the adhesion force of the incise drape and the amount of stripped corneocytes on the peeled drape were comparable between OLG-T- and OLG-C-applied skin, but both were less than those of PVP-I-applied skin. The drapes for OLG-T- and OLG-C-applied skin had moderate adhesion force, and the drape-related injuries were expected to be weak. These results suggest that OLG-T performs no worse than OLG-C in terms of its antimicrobial activity and medical adhesive compatibility. Therefore, we expect OLG-T to lead to more convenient preoperative skin preparation and further contribute to lowering surgical site infection rates. |
---|---|
AbstractList | Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this drawback, we realized a stable orange-tinted antiseptic (OLG-T) by adding new additives to OLG-C and investigated its pharmaceutical properties compared with OLG-C and povidone iodine (PVP-I). We evaluated the influence of the additives on the antimicrobial activity and adhesiveness of medical adhesives to OLG-T-applied skin by in vitro time-kill/ex vivo micropig skin assays and a peel test using excised micropig skin, respectively. In the in vitro time-kill assay, the bactericidal/fungicidal activity of OLG-T and OLG-C were equivalent. In the ex vivo micropig skin assay, their fast-acting and persistent bactericidal activities against vancomycin-resistant Enterococcus faecalis were higher than that of PVP-I. In the peel test, the adhesion force of the incise drape and the amount of stripped corneocytes on the peeled drape were comparable between OLG-T- and OLG-C-applied skin, but both were less than those of PVP-I-applied skin. The drapes for OLG-T- and OLG-C-applied skin had moderate adhesion force, and the drape-related injuries were expected to be weak. These results suggest that OLG-T performs no worse than OLG-C in terms of its antimicrobial activity and medical adhesive compatibility. Therefore, we expect OLG-T to lead to more convenient preoperative skin preparation and further contribute to lowering surgical site infection rates. |
ArticleNumber | b21-00833 |
Author | Hayashi, Nahoki Hagi, Akifumi Nii, Takuya Nishioka, Hisae Shiozaki, Mari |
Author_xml | – sequence: 1 fullname: Nishioka, Hisae organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc – sequence: 2 fullname: Shiozaki, Mari organization: Pharmaceutical Technology Department, Technical Center, Otsuka Pharmaceutical Factory, Inc – sequence: 3 fullname: Nii, Takuya organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc – sequence: 4 fullname: Hayashi, Nahoki organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc – sequence: 5 fullname: Hagi, Akifumi organization: Naruto Research Institute, Research and Development Center, Otsuka Pharmaceutical Factory, Inc |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34819410$$D View this record in MEDLINE/PubMed |
BookMark | eNpdkT1vFDEQhi0URC6BkhZZoqHIBn_uR3mcSECKlBShtrz27MWnXXuxvRL8e7y55AqasTR-5tVongt05oMHhD5Sck2ZaL_2c3_dM1oR0nL-Bm0oF00lGZVnaEM62lY1le05ukjpQAhpCOPv0DkXLe0EJRv09PCk46QNLNkZPeKHGGaI2UHCYcAaPzqfweKbEKdl1NkFf-x_c_tFe2cBb312CeYyjrd78PkK34_awx9nnQd8Oy4meJ3hPXo76DHBh5f3Ev26-f64-1Hd3d_-3G3vKiMZz5WmZtC90JRS0zRtx9Y6CE5qEIJIO7QDr7vagCGdMW3DeGe1BWst1EY0nF-iL8fcOYbfC6SsJpcMjOtOYUmK1YTVXAq5op__Qw9hib5sVygmGiIpFYWqjpSJIaUIg5qjm3T8qyhRqwJVFKiiQD0rKPynl9Sln8Ce6NebF2B3BA4p6z2cAF3ObkZ4jhNSsbWcYk-_pvhS4Pk_k5Sb7A |
Cites_doi | 10.1001/jamasurg.2017.0904 10.1111/j.1600-0846.2005.00088.x 10.1007/978-1-4613-0671-9_22 10.1248/cpb.58.1366 10.1007/s00423-020-02007-6 10.1001/archsurg.1985.01390360023006 10.1097/WON.0b013e3182995516 10.1201/9780203909256.ch24 10.1016/j.ajic.2008.12.008 10.1016/j.ajic.2008.12.010 10.1099/jmm.0.000870 10.1016/S1473-3099(20)30281-4 10.1128/AAC.05048-14 10.1007/978-1-60761-594-1_22 10.1016/S1473-3099(20)30225-5 10.1248/bpb.34.555 10.1021/acs.jmedchem.7b00010 10.1016/S0195-6701(08)60017-1 10.1016/j.jhin.2004.06.030 10.1248/bpb.b18-00821 10.1086/501572 10.1021/acsomega.9b03305 10.1016/j.jos.2019.07.008 10.1099/jmm.0.080861-0 10.1128/CMR.14.2.244-269.2001 10.1177/175045891302301104 |
ContentType | Journal Article |
Copyright | 2022 The Pharmaceutical Society of Japan Copyright Japan Science and Technology Agency 2022 |
Copyright_xml | – notice: 2022 The Pharmaceutical Society of Japan – notice: Copyright Japan Science and Technology Agency 2022 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
DOI | 10.1248/bpb.b21-00833 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Calcium & Calcified Tissue Abstracts Chemoreception Abstracts Neurosciences Abstracts Virology and AIDS Abstracts Technology Research Database Engineering Research Database AIDS and Cancer Research Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Virology and AIDS Abstracts Technology Research Database AIDS and Cancer Research Abstracts Chemoreception Abstracts Engineering Research Database Calcium & Calcified Tissue Abstracts Neurosciences Abstracts Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | Virology and AIDS Abstracts MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Anatomy & Physiology Chemistry Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1347-5215 |
EndPage | 225 |
ExternalDocumentID | 10_1248_bpb_b21_00833 34819410 article_bpb_45_2_45_b21_00833_article_char_en |
Genre | Journal Article |
GroupedDBID | --- 23N 2WC 5GY 6J9 ACGFO ACIWK ACPRK ADBBV AENEX AFFNX AFRAH ALMA_UNASSIGNED_HOLDINGS BAWUL BKOMP CS3 DIK DU5 E3Z EBS EJD F5P GX1 HH5 JMI JSF JSH KQ8 MOJWN OK1 P2P RJT RZJ TR2 XSB CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QP 7QR 7TK 7U9 8FD FR3 H94 P64 7X8 |
ID | FETCH-LOGICAL-c523t-a1cfab4a111c77892c778f4306e4405df8f3696cec09cc87239dadeddde6c4733 |
ISSN | 0918-6158 |
IngestDate | Thu Apr 11 23:05:00 EDT 2024 Thu Oct 10 19:19:54 EDT 2024 Fri Aug 23 01:03:17 EDT 2024 Thu May 23 23:37:08 EDT 2024 Thu Aug 17 20:30:34 EDT 2023 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | antiseptic persistence antimicrobial activity ex vivo skin model olanexidine peel test |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c523t-a1cfab4a111c77892c778f4306e4405df8f3696cec09cc87239dadeddde6c4733 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | https://www.jstage.jst.go.jp/article/bpb/45/2/45_b21-00833/_article/-char/en |
PMID | 34819410 |
PQID | 2624705114 |
PQPubID | 1966364 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_2602635453 proquest_journals_2624705114 crossref_primary_10_1248_bpb_b21_00833 pubmed_primary_34819410 jstage_primary_article_bpb_45_2_45_b21_00833_article_char_en |
PublicationCentury | 2000 |
PublicationDate | 2022-02-01 |
PublicationDateYYYYMMDD | 2022-02-01 |
PublicationDate_xml | – month: 02 year: 2022 text: 2022-02-01 day: 01 |
PublicationDecade | 2020 |
PublicationPlace | Japan |
PublicationPlace_xml | – name: Japan – name: Tokyo |
PublicationTitle | Biological & pharmaceutical bulletin |
PublicationTitleAlternate | Biol Pharm Bull |
PublicationYear | 2022 |
Publisher | The Pharmaceutical Society of Japan Japan Science and Technology Agency |
Publisher_xml | – name: The Pharmaceutical Society of Japan – name: Japan Science and Technology Agency |
References | 18) “ASTM International E 1054-08 (Reapproved 2013). Standard test methods for evaluation of inactivators of antimicrobial agents.”: ‹https://www.astm.org/e1054-08r13.html›, accessed 4 May, 2021. 10) Harihara Y. [Experience with used the olanexidine-containing preoperative skin antiseptic]. Shujyutsu Igaku (Journal of Japanese Association for Operating Room Technology), 41, 16–20 (2020). 25) Bowler PG, Duerden BI, Armstrong DG. Wound microbiology and associated approaches to wound management. Clin. Microbiol. Rev., 14, 244–269 (2001). 29) Chow J, Ng J, Pun A. Effects of food colouring added to 2% chlorhexidine gluconate and 70% alcohol for surgical site antisepsis. J. Perioper. Pract., 23, 255–257 (2013). 17) Beausoleil CM. A guide for validation of neutralizer systems used in topical antimicrobial efficacy evaluations. Handbook of topical antimicrobials. (Paulson DS ed.) Marcel Dekker, New York, pp. 365–376 (2003). 4) National Institute for Health and Care Excellence. “Surgical site infections: prevention and treatment. NICE guideline [NG125].” (Last updated 19 August 2020): ‹https://www.nice.org.uk/guidance/ng125›, accessed 28 September, 2021. 6) Inoue Y, Hagi A, Nii T, Tsubotani Y, Nakata H, Iwata K. Novel antiseptic compound OPB-2045G shows potent bactericidal activity against methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus both in vitro and in vivo: a pilot study in animals. J. Med. Microbiol., 64, 32–36 (2015). 20) Gaonkar TA, Geraldo I, Caraos L, Modak SM. An alcohol hand rub containing a synergistic combination of an emollient and preservatives: prolonged activity against transient pathogens. J. Hosp. Infect., 59, 12–18 (2005). 5) Hagi A, Iwata K, Nii T, Nakata H, Tsubotani Y, Inoue Y. Bactericidal effects and mechanism of action of olanexidine gluconate, a new antiseptic. Antimicrob. Agents Chemother., 59, 4551–4559 (2015). 11) Obara H, Takeuchi M, Kawakubo H, Shinoda M, Okabayashi K, Hayashi K, Sekimoto Y, Maeda Y, Kondo T, Sato Y, Kitagawa Y. Aqueous olanexidine versus aqueous povidone-iodine for surgical skin antisepsis on the incidence of surgical site infections after clean-contaminated surgery: a multicentre, prospective, blinded-endpoint, randomised controlled trial. Lancet Infect. Dis., 20, 1281–1289 (2020). 13) Willy C, Vogt D. Should olanexidine be used routinely for surgical skin antisepsis? Lancet Infect. Dis., 20, 1219–1220 (2020). 8) Flick AC, Ding HX, Leverett CA, Kyne RE Jr, Liu KK, Fink SJ, O’Donnell CJ. Synthetic approaches to the new drugs approved during 2015. J. Med. Chem., 60, 6480–6515 (2017). 30) Tokumura F, Umekage K, Sado M, Otsuka S, Suda S, Taniguchi M, Yamori A, Nakamura A, Kawai J, Oka K. Skin irritation due to repetitive application of adhesive tape: the influence of adhesive strength and seasonal variability. Skin Res. Technol., 11, 102–106 (2005). 32) Chen X, Taguchi T. Enhanced skin adhesive property of hydrophobically modified poly(vinyl alcohol) films. ACS Omega, 5, 1519–1527 (2020). 34) Nishiwaki Y, Matsunaga T, Kumasaki M. Study of the hygroscopic deterioration of ammonium perchlorate/magnesium mixture. Sci. Tech. Energetic Materials, 79, 15–21 (2018). ‹http://www.jes.or.jp/mag/stem/Vol.79/documents/Vol.79,No.1,p.15-21.pdf.›. 15) McNichol L, Lund C, Rosen T, Gray M. Medical adhesives and patient safety: state of the science:consensus statements for the assessment, prevention, and treatment of adhesive-related skin injuries. J. Wound Ostomy Continence Nurs., 40, 365–380, quiz, E1–E2 (2013). 31) Jaffe HL, Rosenblum FM. Poly(vinyl alcohol) for adhesives. Handbook of Adhesives. Springer, Boston, pp. 401–407 (1990). 3) Berríos-Torres SI, Umscheid CA, Bratzler DW, Leas B, Stone EC, Kelz RR, Reinke CE, Morgan S, Solomkin JS, Mazuski JE, Dellinger EP, Itani KMF, Berbari EF, Segreti J, Parvizi J, Blanchard J, Allen G, Kluytmans JAJW, Donlan R, Schecter WP. Centers for Disease Control and Prevention guideline for the prevention of surgical site infection, 2017. JAMA Surg., 152, 784–791 (2017). 23) Nakano Y, Saito K. Quantitative method for evaluating skin irritation caused by medical adhesives. Nitto Technical Report, 28, 50–57 (1990). 9) Asukai M, Ohishi T, Fujita T, Suzuki D, Nishida T, Sugiura K, Matsuyama Y. Olanexidine gluconate versus povidone-iodine for preventing surgical-site infection in orthopaedic surgery: a retrospective study. J. Orthop. Sci., 24, 1125–1129 (2019). 16) “ASTM International E 2315-16. Standard guide for assessment of antimicrobial activity using a time-kill procedure.” ‹https://www.astm.org/e2315-16.html›, accessed 27 December, 2016. 19) Kaiser N, Klein D, Karanja P, Greten Z, Newman J. Inactivation of chlorhexidine gluconate on skin by incompatible alcohol hand sanitizing gels. Am. J. Infect. Control, 37, 569–573 (2009). 21) Rubinchik E, Pasetka C. Ex vivo skin infection model. Methods Mol. Biol., 618, 359–369 (2010). 1) Kirkland KB, Briggs JP, Trivette SL, Wilkinson WE, Sexton DJ. The impact of surgical-site infections in the 1990 s: attributable mortality, excess length of hospitalization, and extra costs. Infect. Control Hosp. Epidemiol., 20, 725–730 (1999). 33) Xiang C, Wang Y, Zhan X, Luo L, Li L, Li C. Calculating critical relative humidity from solubility according to Pitzer ion interaction model. Chem. Pharm. Bull., 58, 1366–1368 (2010). 2) de Lissovoy G, Fraeman K, Hutchins V, Murphy D, Song D, Vaughn BB. Surgical site infection: incidence and impact on hospital utilization and treatment costs. Am. J. Infect. Control, 37, 387–397 (2009). 24) The Ministry of Health. Labour and Welfare. Methods of adhesion testing. The Japanese Pharmacopoeia Seventeenth Edition. The Ministry of Health, Labour and Welfare, Tokyo, pp. 161–163 (2016).: ‹https://www.mhlw.go.jp/file/06-Seisakujouhou-11120000-Iyakushokuhinkyoku/JP17_REV_1.pdf›, accessed 28 September, 2021. 14) Alexander JW, Aerni S, Plettner JP. Development of a safe and effective one-minute preoperative skin preparation. Arch. Surg., 120, 1357–1361 (1985). 7) Seyama S, Nishioka H, Nakaminami H, Nakase K, Wajima T, Hagi A, Noguchi N. Evaluation of in vitro bactericidal activity of 1.5% olanexidine gluconate, a novel biguanide antiseptic agent. Biol. Pharm. Bull., 42, 512–515 (2019). 12) Yamamoto M, Hara K, Sugezawa K, Uejima C, Tanio A, Tada Y, Shishido Y, Miyatani K, Hanaki T, Kihara K, Matsunaga T, Tokuyasu N, Takano S, Sakamoto T, Honjo S, Fujiwara Y. Disinfection with single or double usage of new antiseptic olanexidine gluconate in general surgery: a randomized study. Langenbecks Arch. Surg., 405, 1183–1189 (2020). 28) Takeuchi H, Terasaka S, Sakurai T, Furuya A, Urano H, Sugibayashi K. Variation assessment for in vitro permeabilities through Yucatan micropig skin. Biol. Pharm. Bull., 34, 555–561 (2011). 22) Nishioka H, Nagahama A, Inoue Y, Hagi A. Evaluation of fast-acting bactericidal activity and substantivity of an antiseptic agent, olanexidine gluconate, using an ex vivo skin model. J. Med. Microbiol., 67, 1796–1803 (2018). 26) Owens CD, Stoessel K. Surgical site infections: epidemiology, microbiology and prevention. J. Hosp. Infect., 70 (Suppl. 2), 3–10 (2008). 27) Lavker RM, Dong G, Zheng PS, Murphy GF. Hairless micropig skin. A novel model for studies of cutaneous biology. Am. J. Pathol., 138, 687–697 (1991). 22 23 24 25 26 27 28 29 30 31 10 32 11 33 12 34 13 14 15 16 17 18 19 1 2 3 4 5 6 7 8 9 20 21 |
References_xml | – ident: 3 doi: 10.1001/jamasurg.2017.0904 – ident: 18 – ident: 4 – ident: 30 doi: 10.1111/j.1600-0846.2005.00088.x – ident: 31 doi: 10.1007/978-1-4613-0671-9_22 – ident: 33 doi: 10.1248/cpb.58.1366 – ident: 12 doi: 10.1007/s00423-020-02007-6 – ident: 10 – ident: 14 doi: 10.1001/archsurg.1985.01390360023006 – ident: 16 – ident: 15 doi: 10.1097/WON.0b013e3182995516 – ident: 17 doi: 10.1201/9780203909256.ch24 – ident: 19 doi: 10.1016/j.ajic.2008.12.008 – ident: 2 doi: 10.1016/j.ajic.2008.12.010 – ident: 24 – ident: 22 doi: 10.1099/jmm.0.000870 – ident: 13 doi: 10.1016/S1473-3099(20)30281-4 – ident: 5 doi: 10.1128/AAC.05048-14 – ident: 21 doi: 10.1007/978-1-60761-594-1_22 – ident: 11 doi: 10.1016/S1473-3099(20)30225-5 – ident: 28 doi: 10.1248/bpb.34.555 – ident: 8 doi: 10.1021/acs.jmedchem.7b00010 – ident: 26 doi: 10.1016/S0195-6701(08)60017-1 – ident: 20 doi: 10.1016/j.jhin.2004.06.030 – ident: 34 – ident: 7 doi: 10.1248/bpb.b18-00821 – ident: 1 doi: 10.1086/501572 – ident: 32 doi: 10.1021/acsomega.9b03305 – ident: 9 doi: 10.1016/j.jos.2019.07.008 – ident: 6 doi: 10.1099/jmm.0.080861-0 – ident: 25 doi: 10.1128/CMR.14.2.244-269.2001 – ident: 29 doi: 10.1177/175045891302301104 – ident: 27 – ident: 23 |
SSID | ssj0007023 |
Score | 2.3910809 |
Snippet | Olanexidine gluconate-containing preoperative antiseptic (OLG-C) is colorless, which makes it difficult to determine its area of application. To overcome this... |
SourceID | proquest crossref pubmed jstage |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 220 |
SubjectTerms | Adhesiveness Animals Anti-Infective Agents, Local - administration & dosage Antimicrobial activity Antimicrobial agents antiseptic Azo Compounds - administration & dosage Bacteria - drug effects Bacteria - growth & development Biguanides - administration & dosage Drug Compounding ex vivo skin model Female Food Coloring Agents - administration & dosage Fungicidal activity Glucuronates - administration & dosage Iodine olanexidine peel test persistence Povidone Skin - drug effects Skin - microbiology Skin tests Surgical site infections Swine Vancomycin |
Title | Pharmaceutical Properties of a Tinted Formulation of a Biguanide Antiseptic Agent, Olanexidine Gluconate |
URI | https://www.jstage.jst.go.jp/article/bpb/45/2/45_b21-00833/_article/-char/en https://www.ncbi.nlm.nih.gov/pubmed/34819410 https://www.proquest.com/docview/2624705114 https://search.proquest.com/docview/2602635453 |
Volume | 45 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
ispartofPNX | Biological and Pharmaceutical Bulletin, 2022/02/01, Vol.45(2), pp.220-225 |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKQLAXBB0fhYGMhPpCM5rETWKJlzIxKiRgEp20t8h2kjVUS6q1lej457mzEycRTAJerMp2Giu_X8538X0Q8tqdqCDgPnekkGCgRKHvRBI9pyKMynSRBNrb4kswO2Ofzifnvd7PdnTJRh6p6z_GlfwPqtAHuGKU7D8ga_8UOuA34AstIAztX2F8uuh8kD7FD-tXmCHVRD3OMRdE8uYE1NKqSJfpf59fbEWRJ5iSBGsxrzBp6xRjrPCBf0X31x95gurnR3RoL8Sm4y9kylfqOyJvVt1FyHY-b3PgscjLpdZRZ_laWCJ9g-5rYapmfwaLvblAd83FcrsTjYDcYdUnsx8symXe_loBhu7Yen6kRsL6LATr18Rw1iLYZJSsqOa15amOlPtdznsMYxfkSh5Jz3VQj_Tb8wCm1aUGHeOMOas8Z7uJteuhW-S2B1Iq0lK9sZ1C0GaqpKxwt7ede-2Tu_XVHX3mzndQ6S_Sm60VrbXMH5D7lblBp4Y7D0kvLfrkYAqQlpc7OqTaAVifrPTJveO6-F-fDCtq7UZ03kTorUf6EpvsfHdAFl0O0oaDtMyooIaDtMVB0285SBsOUs3BEW0xkFoGPiJnJx_mxzOnqt7hqInnbxzhqkxIJuCFV2EYcQ_bjIGJmjKwEpIsyrCWpErVmCsVhZ7PE5GkCey3gWKh7z8me0VZpE8JFT7sPJmruAvGShAlkqcZZ-OQhyCCuBIDMqwxiFcmSUuMxi3gFgNuMeAWa9wG5J1ByE6r3l09jU1iDxs73Y5iBCQInAE5rHGNKzGwjr3AYyFsbS4bkFd2GODCkzd4XOUW54wx6RObwAqeGD7YFdREenbjyHOy37xKh2Rvc7VNX4AqvJEvNWV_AdAMtlc |
link.rule.ids | 315,783,787,27938,27939 |
linkProvider | ABC ChemistRy |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Pharmaceutical+Properties+of+a+Tinted+Formulation+of+a+Biguanide+Antiseptic+Agent%2C+Olanexidine+Gluconate&rft.jtitle=Biological+%26+pharmaceutical+bulletin&rft.au=Nishioka%2C+Hisae&rft.au=Shiozaki%2C+Mari&rft.au=Nii%2C+Takuya&rft.au=Hayashi%2C+Nahoki&rft.date=2022-02-01&rft.eissn=1347-5215&rft.volume=45&rft.issue=2&rft.spage=220&rft_id=info:doi/10.1248%2Fbpb.b21-00833&rft_id=info%3Apmid%2F34819410&rft.externalDocID=34819410 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0918-6158&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0918-6158&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0918-6158&client=summon |